|Slideshows|October 4, 2021

The Cognitive Benefits of Matcha

A study compared matcha, a highly caffeinated green tea, to other sources of caffeine. Which had the greatest cognitive benefits?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Oveporexton Improves Daily Function, Cognition, and Nighttime Sleep in Narcolepsy Type 1

ByElena Koundourakis, PhD

June 17th 2026

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

ByMark Gerstein, PhD

June 5th 2026

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

ByLeah Kuntz

May 20th 2026

The Clinical Uses and Importance of Lifestyle Medicine in Psychiatry

ByFarah Abbas, BS,Asim A. Shah, MD

April 29th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

The Cognitive Benefits of Matcha

Related Content

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Oveporexton Improves Daily Function, Cognition, and Nighttime Sleep in Narcolepsy Type 1

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

The Clinical Uses and Importance of Lifestyle Medicine in Psychiatry

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Metabolic Risk, Residual Insomnia, and Seltorexant